Literature DB >> 3036328

Expression of ABH and Lewis blood group antigens in combined hepatocellular-cholangiocarcinoma. Possible evidence for the hepatocellular origin of combined hepatocellular-cholangiocarcinoma.

Y Okada, K Jinno, S Moriwaki, S Morichika, S Torigoe, T Arima, H Nagashima, H Koprowski.   

Abstract

Expression of ABH, Lewis, and sialyl Lea antigens was studied in five combined hepatocellular-cholangiocarcinomas. Formalin-fixed liver tissues were immunostained for those antigens using well-characterized monoclonal antibodies and an avidin-biotin-peroxidase complex (ABC) method. Results were compared with those obtained in normal liver tissues and cholangiocarcinomas, and also with the previous observations of the authors on hepatocellular carcinomas. Although not detected in normal parenchymal liver cells, A, H, Lewis, and sialyl Lea antigens were found in combined hepatocellular-cholangiocarcinoma cells. Incompatible A antigen also was detected in one blood type O patient. Distribution and intensity of the antigens were similar to those in hepatocellular carcinomas and different from those in cholangiocarcinomas. No preferential accumulation of blood-group antigens could be found in the area of cholangiocarcinoma-like differentiation of the combined hepatocellular-cholangiocarcinoma. The observations suggested that Regional morphological differentiation of the hepatocellular-cholangiocarcinoma might not be always associated with the change in the expression of the blood group antigens. Moreover, the expression was essentially the same between the hepatocellular-cholangiocarcinoma and the typical hepatocellular carcinoma. The hepatocellular-cholangiocarcinoma, therefore could be a variant of the hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036328     DOI: 10.1002/1097-0142(19870801)60:3<345::aid-cncr2820600311>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  The stem cells of the liver--a selective review.

Authors:  K Aterman
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Hepatocellular expression of a novel glycoprotein with sialylated difucosyl Lex activity in the active inflammatory lesions of chronic liver disease.

Authors:  Y Okada; T Shimoe; M Muguruma; R Usumoto; T Tsuji; K Jinno; S Moriwaki; S Shin; S Hakomori
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  Combined hepatocellular and cholangiocarcinoma of the liver: sonography, CT, angiography, and iodized-oil CT with pathologic correlation.

Authors:  B I Choi; J K Han; Y I Kim; H C Kim; J H Park; C W Kim; M C Han
Journal:  Abdom Imaging       Date:  1994 Jan-Feb

Review 4.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

5.  Semiquantitative immunohistochemical studies of blood group antigen A, B, H, Le(a), Le(b) structures and Ii backbone chains in the normal human cervix and in cervical adenocarcinoma.

Authors:  N R Griffin; M Wells
Journal:  Histochem J       Date:  1993-03

6.  ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization.

Authors:  Kittipitch Bannangkoon; Keerati Hongsakul; Pimsiri Sripongpun; Apichat Kaewdech; Naichaya Chamroonkul; Teeravut Tubtawee; Teerha Piratvisuth
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

7.  ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.

Authors:  Joyce Yongxu Huang; Renwei Wang; Yu-Tang Gao; Jian-Min Yuan
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.